Biodegradable microspheres containing influenza A vaccine: Immune response in mice

被引:52
作者
Hilbert, AK
Fritzsche, U
Kissel, T [1 ]
机构
[1] Univ Marburg, Dept Pharmaceut & Biopharm, D-35032 Marburg, Germany
[2] Chiron Behring GmbH & Co, Preclin Res, D-35006 Marburg, Germany
关键词
influenza vaccine; biodegradable microspheres; ABA triblock copolymers;
D O I
10.1016/S0264-410X(98)00323-5
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A monovalent influenza split vaccine was microencapsulated in poIy(D,L-lactic-co-glycolic acid) (PLGA) and ABA triblock copolymers using a W/O/W double emulsion technique. To stabilize the antigen, influenza vaccine was also coencapsulated with liposomes. Antigen release from microspheres was determined in vitro using a hemagglutinin-specific ELISA. PLGA-microspheres with liposomes released immunoreactive hemagglutinin in a pulsatile manner, a preferred feature for the development of a single dose vaccine delivery system. Influenza hemagglutinin specific IgG and neutralizing antibody responses were studied in BALB/c mice following subcutaneous injection of different microsphere preparations. PLGA-microspheres elicited a significantly higher primary IgG response compared to nonencapsulated antigen. ABA-microspheres seemed to be less immunogenic than PLGA-microspheres based on the IgG antibody response, however, similar levels of neutralizing antibodies were observed after eight weeks with both polymers. Entrapment of the antigen in liposomes prior to microencapsulation did not further enhance the immune response. The immunopotentating effect of the antigen-loaded microspheres was prominently enhanced when they were given as suspension in fluid antigen, suggesting that free antigen may serve as priming and microencapsulated antigen as booster dose. Eight weeks after a single subcutaneous immunization with PLGA or ABA-microspheres neutralizing antibodies were as high as those obtained after two subcutaneous administrations of fluid vaccine four weeks apart. Microencapsulated influenza antigen may have potential for a single dose vaccine delivery system with adjuvant properties. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1065 / 1073
页数:9
相关论文
共 23 条
[1]   BIODEGRADABLE MICROSPHERES AS CONTROLLED-RELEASE TETANUS TOXOID DELIVERY SYSTEMS [J].
ALONSO, MJ ;
GUPTA, RK ;
MIN, C ;
SIBER, GR ;
LANGER, R .
VACCINE, 1994, 12 (04) :299-306
[2]   Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults [J].
Beyer, WEP ;
Palache, AM ;
Sprenger, MJW ;
Hendriksen, E ;
Tukker, JJ ;
Darioli, R ;
vanderWater, GL ;
Masurel, N ;
Osterhaus, ADME .
VACCINE, 1996, 14 (14) :1331-1339
[3]   FACTORS INFLUENCING THE RELEASE OF PEPTIDES AND PROTEINS FROM BIODEGRADABLE PARENTERAL DEPOT SYSTEMS [J].
BODMER, D ;
KISSEL, T ;
TRAECHSLIN, E .
JOURNAL OF CONTROLLED RELEASE, 1992, 21 (1-3) :129-137
[4]   Stabilization of tetanus toxoid in poly(DL-lactic-co-glycolic acid) microspheres for the controlled release of antigen [J].
Chang, AC ;
Gupta, RK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1996, 85 (02) :129-132
[5]  
DAVENPORT FM, 1968, J IMMUNOL, V100, P1139
[6]   MUCOSAL IMMUNOADJUVANT ACTIVITY OF LIPOSOMES - INDUCTION OF SYSTEMIC IGG AND SECRETORY IGA RESPONSES IN MICE BY INTRANASAL IMMUNIZATION WITH AN INFLUENZA SUBUNIT VACCINE AND COADMINISTERED LIPOSOMES [J].
DEHAAN, A ;
GEERLIGS, HJ ;
HUCHSHORN, JP ;
VANSCHARRENBURG, GJM ;
PALACHE, AM ;
WILSCHUT, J .
VACCINE, 1995, 13 (02) :155-162
[7]   A RANDOMIZED CONTROLLED TRIAL OF COLD-ADAPTED AND INACTIVATED VACCINES FOR THE PREVENTION OF INFLUENZA A DISEASE [J].
EDWARDS, KM ;
DUPONT, WD ;
WESTRICH, MK ;
PLUMMER, WD ;
PALMER, PS ;
WRIGHT, PF .
JOURNAL OF INFECTIOUS DISEASES, 1994, 169 (01) :68-76
[8]   INTRANASAL IMMUNIZATION WITH PROTEOLIPOSOMES PROTECTS AGAINST INFLUENZA [J].
ELGUINK, N ;
KRIS, RM ;
GOODMANSNITKOFF, G ;
SMALL, PA ;
MANNINO, RJ .
VACCINE, 1989, 7 (02) :147-151
[9]   PARAMETERS AFFECTING THE IMMUNOGENICITY OF MICROENCAPSULATED TETANUS TOXOID [J].
ESPARZA, I ;
KISSEL, T .
VACCINE, 1992, 10 (10) :714-720
[10]  
Goepferich Achim, 1996, European Journal of Pharmaceutics and Biopharmaceutics, V42, P1